These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32086567)

  • 1. Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany.
    Diel I; Ansorge S; Hohmann D; Giannopoulou C; Niepel D; Intorcia M
    Support Care Cancer; 2020 Nov; 28(11):5223-5233. PubMed ID: 32086567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany.
    Link H; Diel I; Ohlmann CH; Holtmann L; Kerkmann M;
    Support Care Cancer; 2020 May; 28(5):2175-2184. PubMed ID: 31410600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study.
    Diel IJ; Greil R; Janssen J; Kluike CW; Behera B; Abbasi A; Seesaghur A; Kellner M; Jaeger C; Bjorklof K; Tomova A; Haslbauer F
    Support Care Cancer; 2022 Nov; 30(11):9267-9278. PubMed ID: 36066628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer.
    Hagiwara M; Delea TE; Cong Z; Chung K
    Support Care Cancer; 2014 Jan; 22(1):103-13. PubMed ID: 24000042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
    J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
    J Urol; 2009 Aug; 182(2):509-15; discussion 515-6. PubMed ID: 19524963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
    Oster G; Lamerato L; Glass AG; Richert-Boe KE; Lopez A; Chung K; Richhariya A; Dodge T; Wolff GG; Balakumaran A; Edelsberg J
    Support Care Cancer; 2014 May; 22(5):1363-73. PubMed ID: 24389827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
    Saad F; Sternberg CN; Mulders PFA; Niepel D; Tombal BF
    Cancer Treat Rev; 2018 Jul; 68():25-37. PubMed ID: 29787892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
    Miller K; Steger GG; Niepel D; Lüftner D
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender differences in persistency to bisphosphonates in patients with metastatic breast and prostate cancer.
    Hadji P; Kyvernitakis J; Albert U; Jockwig J; Kostev K
    Int J Clin Pharmacol Ther; 2014 May; 52(5):352-9. PubMed ID: 24691062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence with bisphosphonates in patients with metastatic breast cancer: a retrospective database analysis.
    Hadji P; Ziller V; Kyvernitakis J; Schmidt N; Kostev K
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1149-55. PubMed ID: 23552873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
    Cristino J; Finek J; Jandova P; Kolek M; Pásztor B; Giannopoulou C; Qian Y; Brezina T; Lothgren M
    J Med Econ; 2017 Aug; 20(8):799-812. PubMed ID: 28485692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
    Hadji P; Kyvernitakis I; Kann PH; Niedhart C; Hofbauer LC; Schwarz H; Kurth AA; Thomasius F; Schulte M; Intorcia M; Psachoulia E; Schmid T
    Osteoporos Int; 2016 Oct; 27(10):2967-78. PubMed ID: 27172934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
    Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; Martín M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
    Support Care Cancer; 2016 Jan; 24(1):447-455. PubMed ID: 26335402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.